These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12721563)

  • 1. Splurge or merge?
    Jacobs T
    Nat Biotechnol; 2003 May; 21(5):485. PubMed ID: 12721563
    [No Abstract]   [Full Text] [Related]  

  • 2. UK bidding war amidst merger mania.
    Mitchell P
    Nat Biotechnol; 2003 Apr; 21(4):343-4. PubMed ID: 12665805
    [No Abstract]   [Full Text] [Related]  

  • 3. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 4. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 5. Introduction to multihospital systems.
    Ramirez TL
    Top Health Care Financ; 1992; 18(4):1-23. PubMed ID: 1631882
    [No Abstract]   [Full Text] [Related]  

  • 6. Commercializing biotechnology in the UK.
    Searle S; Graves B; Towler C
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE33-5. PubMed ID: 12874976
    [No Abstract]   [Full Text] [Related]  

  • 7. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 8. The future of multihospital systems.
    Kaiser LR
    Top Health Care Financ; 1992; 18(4):32-45. PubMed ID: 1631884
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 10. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 12. When sponsors become partners.
    Coyle M
    Health Prog; 1999; 80(6):34-7. PubMed ID: 11067051
    [No Abstract]   [Full Text] [Related]  

  • 13. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 14. Paring down the company: the effect of consolidation in the European biotech sector.
    Bassett P
    Nat Biotechnol; 2003 Jul; 21(7):829-30. PubMed ID: 12833105
    [No Abstract]   [Full Text] [Related]  

  • 15. Illumina tussles in court with ABI.
    Powell K
    Nat Biotechnol; 2003 Aug; 21(8):836-7. PubMed ID: 12894184
    [No Abstract]   [Full Text] [Related]  

  • 16. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 17. The status of marketing in multi-hospital systems: a view from the top.
    Tucker LR
    J Hosp Mark; 1990; 4(1):153-87. PubMed ID: 10106886
    [No Abstract]   [Full Text] [Related]  

  • 18. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 19. Local hospital systems: forerunners of regional systems?
    Luke RD
    Front Health Serv Manage; 1992; 9(2):3-51; discussion 62-3. PubMed ID: 10122669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile: Julian Thurston.
    Louët S
    Nat Biotechnol; 2005 May; 23(5):517. PubMed ID: 15877058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.